pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:	**Lung Cancer Canada**
Name of drug and indication under review:	**Osimertinib in for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy**

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?

   ☒ Yes

   ☐ No

   If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)

☐	Operating Funds	☒	Program Funding (e.g., website)
☐	Royalties	☐	Research/educational grants
☐	Gifts	☒	Sponsorship of Events
☐	Honoraria	☐	Other, please specify:

©2016 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

AstraZeneca		
June 28, 2012	$[redacted]	Awareness and Education
November, 2013	$[redacted]	Evening of Hope
November, 2014	$[redacted]	Evening of Hope
December,2014	$[redacted]	Patient Guides
May, 2015	$[redacted]	Evening of Hope
August 2015	$[redacted]	Awareness and Education
December 2015	$[redacted]	Awareness and Education (Faces of Lung Cancer Report)
December 2015	$[redacted]	Awareness and Education (Infographic)
January 2016	$[redacted]	Patient Guides
Total	$[redacted]	

Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date:
April 15, 2016

Name: Shem Singh
Signature:

©2016 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

PAN-CANADIAN ONCOLOGY DRUG REVIEW

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group:	Ontario Lung Association
Name of drug and indication under review:	Tagrisso (Generic name – Osimertinib); Indication – Non-Small Cell Lung Cancer

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
   - x Yes
   - ☐ No

   If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)

☐	Operating Funds	☐	Program Funding (e.g., website)
☐	Royalties	☐	Research/educational grants
☐	Gifts	x	Sponsorship of Events
☐	Honoraria	☐	Other, please specify: _____

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

   Astra Zeneca Canada - $[redacted]

©2016 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

N/A

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

N/A

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: 2016/04/15 Name: Andrea Stevens Lavigne Signature: Andrea Stevens Lavigne

©2016 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW